Navigation Links
International symposium explores genetic link to mesothelioma and other cancers
Date:10/28/2011

HONOLULU--The University of Hawaii Cancer Center and The Queen's Medical Center (QMC) will host an international symposium on Friday, December 2, 2011 from 8:15 a.m. 4:30 p.m. at The Queen's Conference Center Auditorium to discuss new information related to the recent discovery of the BAP1 genetic mutation and its link to mesothelioma, melanoma and potentially other cancers.

The Third Annual Translational Cancer Medicine Symposium will feature more than 20 global experts in cancer genetics including keynote speaker, Carlo M. Croce, M.D., Director of the Human Cancer Genetics Program of The Ohio State University; Joseph Testa, Ph.D., Director of the Genomics Facility at Fox Chase Cancer Center; and Michele Carbone, M.D., Ph.D., Director of the University of Hawaii Cancer Center whose research team announced in August its discovery of the BAP1 gene mutation's link to mesothelioma and other cancers. "We are excited to bring these experts to Hawaii to work together to find ways to reduce the suffering and death from cancers caused by this mutation," said Carbone.

The BAP1 cancer syndrome is caused by inherited mutations of the BAP1 gene. Carriers of the BAP1 mutation can develop mesothelioma, uveal melanoma, melanocytic tumors and other carcinomas. When individuals with the BAP1 mutation are exposed to asbestos or erionite, mesothelioma appears to predominate and may be the cause of death in 50% of family members. This discovery provides physicians with a new tool to identify individuals at very high risk of developing these types of cancers. The study on the BAP1 discovery was published online in Nature Genetics on August 28, 2011.

Mesothelioma tumors are typically associated with asbestos and erionite exposure. Erionite, a naturally occurring mineral fiber similar to asbestos, is found in rock formations and volcanic ash. A small fraction of individuals exposed to erionite or asbestos actually develop mesothelioma, one of the deadliest forms of cancer that kills about 3,000 people each year in the United States, with half of those diagnosed dying within one year. Rates of new cases of mesothelioma in parts of the world, including Europe and China, have risen steadily over the past decade.

Funding for this event is provided by the Weinman Foundation's Innovators in Cancer Research Fund. This Fund was established in 2008 for the University of Hawaii Cancer Center by Barry and Virginia Weinman to promote translational cancer research aimed at moving cancer research findings to the patient's bedside. The Fund brings prominent leaders in cancer research to Hawaii each year to establish research collaborations with the University of Hawaii Cancer Center and members of the University of Hawaii Cancer Consortium.

The event is intended for researchers and healthcare professionals, and the cost for attendance is $40. For more information or to register call (808) 691-4406 or email at cme@queens.org.


'/>"/>

Contact: Kevin Cassel
kevin@cc.hawaii.edu
808-564-5916
University of Hawaii Cancer Center
Source:Eurekalert

Related biology news :

1. Launch of BioLynx provides a boost for the international malaria research community
2. Fate of lakes focus of international meeting in Sunapee, N.H.
3. AACR hosts 10th International Conference on Frontiers in Cancer Prevention Research
4. Wiley-Blackwell signs three new international open access agreements
5. International study identifies new gene targets for hypertension treatment
6. Media invited: AVS 58th International Symposium and Exhibition
7. Mapping a model: International research on plant species appears in journal Nature
8. Systech International and Zetes Partner to Meet Europes Emerging Pharmaceutical Regulatory Requirements
9. Thermophile experts to hold international meeting Sept. 11-16 near Yellowstone National Park
10. International pharmacogenomics conference to focus on better drug treatment based on genetics
11. American Society of Human Genetics to host 12th International Congress of Human Genetics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/15/2016)... April 15, 2016  A new partnership announced ... accurate underwriting decisions in a fraction of the ... priced and high-value life insurance policies to consumers ... With Force Diagnostics, rapid testing (A1C, Cotinine ... readings (blood pressure, weight, pulse, BMI, and activity ...
(Date:4/13/2016)... 2016  IMPOWER physicians supporting Medicaid patients in ... clinical standard in telehealth thanks to a new partnership ... platform, IMPOWER patients can routinely track key health measurements, ... index, and, when they opt in, share them with ... a local retail location at no cost. By leveraging ...
(Date:3/29/2016)... , March 29, 2016 LegacyXChange, ... LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to announce ... used in a variety of writing instruments, ensuring athletes ... originally created collectibles from athletes on LegacyXChange will be ... of the DNA. Bill Bollander , ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... is pleased to announce the launch of their brand, UP4™ Probiotics, into Target ... over 35 years, is proud to add Target to its list of well-respected ...
(Date:6/23/2016)... 23, 2016 Houston Methodist Willowbrook Hospital ... Sports Association to serve as their official health ... Methodist Willowbrook will provide sponsorship support, athletic training ... association coaches, volunteers, athletes and families. ... Sports Association and to bring Houston Methodist quality ...
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology: